Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes

AIM: Cetuximab is a standard-of-care treatment for KRAS wild-type metastatic colorectal cancer (mCRC), but it may also be effective in a subgroup of KRAS mutant patients by its immunomodulatory activity. Here, we explore if KIR (killer cell immunoglobulin-like receptor) genotyping can provide a sign...

Descripción completa

Detalles Bibliográficos
Autores principales: Manzanares-Martin, Barbara, Cebrián Aranda, Arancha, del Puerto-Nevado, Laura, González, Rafael, Solanes, Sonia, Gómez-España, Maria Auxiliadora, García-Foncillas, Jesús, Aranda, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immunotherapy Biomarkers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039212/
https://www.ncbi.nlm.nih.gov/pubmed/33833048
http://dx.doi.org/10.1136/jitc-2020-001705

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039212/
https://www.ncbi.nlm.nih.gov/pubmed/33833048
http://dx.doi.org/10.1136/jitc-2020-001705

Ejemplares similares